-
The End Brain Cancer Initiative Partners with Curis to Pre-qualify for PCNSL TakeAim Lymphoma Clinical Trial
17 Jun 2025 00:00 GMT
… Genentech, a member of the Roche Group, under which they are commercializing …
-
AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence
16 Jun 2025 22:27 GMT
… Genentech, a member of the Roche Group, in the United States and …
-
Swiss Shares Extend Friday's Losses
16 Jun 2025 23:08 GMT
… Gruppe gained 0.61 percent, Roche Holding stumbled 2.52 percent, Swatch …
-
Genentech Provides Update on Phase III Verona Study
16 Jun 2025 15:49 GMT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), … Genentech, a member of the Roche Group. It is jointly commercialized by … company, a member of the Roche Group, has headquarters in South San …
-
Glucagon-Like Peptide GLP-1 Agonists Weight Loss Drugs Market Forecast To 2034 – For Business Leaders & Strategic Teams
16 Jun 2025 12:07 GMT
… drugs market include Pfizer Inc., Roche Holding AG, Merck & Co. Inc …
-
Dementia Treatment Global Market To Reach $20.14 Billion In 2025 With A 9.9 % CAGR
16 Jun 2025 12:06 GMT
… the dementia treatment market are Roche Holding AG, AbbVie Inc., Sanofi S …
-
Gene Silencing Market Report 2025 – Strategic Insights For Companies Seeking Expansion, Growth & Competitive Advantage
16 Jun 2025 11:39 GMT
… the gene silencing market include Roche Holding AG, Merck & Co. Inc …
-
Roche To Advance Prasinezumab Into Phase III Development For Early-Stage Parkinson's Disease
16 Jun 2025 06:13 GMT
… wholly owned member of the Roche Group. Roche is the majority shareholder in …
-
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson’s Disease
16 Jun 2025 05:49 GMT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), … company, a member of the Roche Group, has headquarters in South San …
-
Experimental obesity drug shows promise
15 Jun 2025 21:50 GMT
… ’s hottest market.
In March, Roche Holding AG entered into a $5 …